Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025

Rhea-AI Summary

Protara Therapeutics (Nasdaq: TARA) will host a conference call and live webcast at 8:30 am ET on Wednesday, December 3, 2025 to review new interim data from the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in BCG-naïve non-muscle invasive bladder cancer (NMIBC) patients.

The interim data will also be presented in a poster session at the 26th Annual Meeting of the Society of Urologic Oncology (SUO). The company will provide an update on feedback received from the U.S. Food and Drug Administration concerning a registrational path forward for TARA-002 in BCG-naïve patients. A replay and slides will be archived for a limited time.

News Market Reaction

-8.67%

18 alerts

-8.67% News Effect

+6.4% Peak Tracked

-6.2% Trough Tracked

-$25M Valuation Impact

$266M Market Cap

1.1x Rel. Volume

On the day this news was published, TARA declined 8.67%, reflecting a notable negative market reaction. Argus tracked a peak move of +6.4% during that session. Argus tracked a trough of -6.2% from its starting point during tracking. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $25M from the company's valuation, bringing the market cap to $266M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Trial phase: Phase 2 Event time: 8:30 a.m. ET Conference edition: 26th Annual Meeting +1 more

4 metrics

Trial phase Phase 2 ADVANCED-2 trial of TARA-002 in BCG-naïve NMIBC

Event time 8:30 a.m. ET Conference call and webcast on December 3, 2025

Conference edition 26th Annual Meeting Society of Urologic Oncology (SUO) meeting hosting poster session

Market cap $296,360,442 Before interim data review announcement

Market Reality Check

Price: $5.77 Vol: Volume 1,604,647 is 1.35x...

normal vol

$5.77 Last Close

Volume Volume 1,604,647 is 1.35x the 20-day average of 1,185,940, indicating elevated interest ahead of the call. normal

Technical Shares at $6.01 are trading above the 200-day MA of $4.00 and 116.97% above the 52-week low, but 23.15% below the 52-week high.

Peers on Argus

Biotech peers showed mixed moves, with BMEA at -6.58%, CRBP at -5.76%, and EQ at...

1 Up 2 Down

Biotech peers showed mixed moves, with BMEA at -6.58%, CRBP at -5.76%, and EQ at +4.43%. This points to stock-specific factors rather than a unified sector trend around this announcement.

Historical Context

5 past events · Latest: Dec 08 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 08	Equity offering close	Negative	+0.3%	Closing of $75M underwritten public offering at $5.75 per share.
Dec 04	Equity offering pricing	Negative	+0.7%	Pricing of $75M offering of 13,043,479 shares at $5.75.
Dec 04	Equity offering proposal	Negative	+0.7%	Proposed $75M public offering of common stock and pre-funded warrants.
Dec 03	ADVANCED-2 data update	Positive	+9.3%	Updated interim Phase 2 ADVANCED-2 data and supportive FDA feedback.
Dec 01	Conference call notice	Positive	-8.7%	Announcement of webcast to review new ADVANCED-2 interim data.

Pattern Detected

Recent history shows strong positive reaction to substantive ADVANCED-2 data (+9.32%), while financing headlines and prior conference-call announcements often produced small gains or declines, indicating investors differentiate between actual data releases and preparatory or financing news.

Recent Company History

Over late 2025, Protara combined clinical progress on TARA-002 with significant financing. On Dec 3, 2025, updated ADVANCED-2 data in BCG-naïve NMIBC drove a +9.32% move, highlighting market enthusiasm for strong efficacy and FDA feedback. Surrounding this, three $75M offering announcements (proposed, pricing, closing) on Dec 4–8 saw modest positive reactions. A prior conference/webcast notice on Dec 1, 2025 triggered an -8.67% move, underscoring that investors have reacted more favorably to concrete data than to event announcements.

Market Pulse Summary

The stock moved -8.7% in the session following this news. A negative reaction despite the scheduling...

Analysis

The stock moved -8.7% in the session following this news. A negative reaction despite the scheduling of new ADVANCED-2 data would echo the -8.67% move seen on the earlier December 1, 2025 conference-call notice, when investors sold ahead of results. Past trading shows stronger support for actual efficacy and FDA feedback, like the +9.32% move on data release, than for event logistics, so disappointment or risk-off positioning could have amplified downside.

Key Terms

phase 2, bcg-naïve, non-muscle invasive bladder cancer, nmibc, +1 more

5 terms

phase 2 medical

"interim analysis of the ongoing Phase 2 open-label ADVANCED-2 trial"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

bcg-naïve medical

"ADVANCED-2 trial of TARA-002 in BCG-Naïve patients with non-muscle invasive"

BCG-naïve describes patients who have never received Bacillus Calmette–Guérin (BCG) therapy, a common first-line immunotherapy for certain bladder cancers. For investors, this matters because drugs or devices tested or approved for BCG-naïve patients address a different group and potential market size than treatments for those who already failed BCG; think of it like a product aimed at first-time buyers versus repeat customers.

non-muscle invasive bladder cancer medical

"BCG-Naïve patients with non-muscle invasive bladder cancer (NMIBC)."

A form of bladder cancer that is confined to the inner lining of the bladder and has not grown into the deeper muscle layer; think of it like a stain on wallpaper rather than damage to the wall’s studs. It matters to investors because it has different treatment, monitoring and recurrence patterns than deeper cancers, driving demand for repeated outpatient procedures, local therapies and diagnostic tests that affect revenue, trial design and pricing dynamics in healthcare markets.

nmibc medical

"BCG-Naïve patients with non-muscle invasive bladder cancer (NMIBC)."

A common form of bladder cancer that stays confined to the bladder’s inner lining or the layer just below it and has not grown into the deeper muscle wall. It matters to investors because it often requires repeated procedures, ongoing surveillance and long-term treatments, creating a sizable and stable market for diagnostics, drugs and medical devices; think of it like a surface-level problem that needs frequent check-ups and follow-up care rather than a one-time fix.

u.s. food and drug administration regulatory

"update on feedback from the U.S. Food and Drug Administration on a registrational path"

The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.

AI-generated analysis. Not financial advice.

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it will host a conference call and live webcast at 8:30 am ET on Wednesday, December 3, 2025, to review new data from an interim analysis of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in BCG-Naïve patients with non-muscle invasive bladder cancer (NMIBC). The data will be featured during a poster session at the 26th Annual Meeting of the Society of Urologic Oncology (SUO). The Company will also provide an update on feedback from the U.S. Food and Drug Administration on a registrational path forward for TARA-002 in BCG-Naïve patients.

The live event and accompanying slides can be accessed by visiting https://protara-therapeutics-suo-update-call.open-exchange.net/registration or via the Events and Presentations section of the Company’s website: https://ir.protaratx.com. A replay of the webcast will be archived for a limited time following the event.

About Protara Therapeutics, Inc.

Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin, as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Protara may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “designed,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words or expressions referencing future events, conditions or circumstances that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include but are not limited to, statements regarding Protara’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: Protara’s business strategy, including its development plans for its product candidates and plans regarding the timing or outcome of existing or future clinical trials (including the timing of any particular phases of such trials and the timing of the announcement of any data produced during such trials or phases thereof); statements related to expectations regarding interactions with the U.S. Food and Drug Administration (FDA); Protara’s financial position; statements regarding the anticipated safety or efficacy of Protara’s product candidates; and Protara’s outlook for the remainder of the year and future periods. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that contribute to the uncertain nature of the forward-looking statements include: risks that Protara’s financial guidance may not be as expected, as well as risks and uncertainties associated with: Protara’s development programs, including the initiation and completion of non-clinical studies and clinical trials and the timing of required filings with the FDA and other regulatory agencies; general market conditions; changes in the competitive landscape; changes in Protara’s strategic and commercial plans; Protara’s ability to obtain sufficient financing to fund its strategic plans and commercialization efforts; having to use cash in ways or on timing other than expected; the impact of market volatility on cash reserves; failure to attract and retain management and key personnel; the impact of general U.S. and foreign, economic, industry, market, regulatory, political or public health conditions; and the risks and uncertainties associated with Protara’s business and financial condition in general, including the risks and uncertainties described more fully under the caption “Risk Factors” and elsewhere in Protara's filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Protara undertakes no obligation to update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as required by law.

Company Contact:

Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836

FAQ

When will Protara Therapeutics (TARA) present interim ADVANCED-2 data and when is the webcast?

The company will review interim ADVANCED-2 data on a conference call and webcast at 8:30 am ET on December 3, 2025.

Where will Protara present the TARA-002 ADVANCED-2 interim results?

The interim data will be featured during a poster session at the 26th Annual Meeting of the Society of Urologic Oncology (SUO).

How can investors access the Protara (TARA) live event and slides for the December 3, 2025 presentation?

Access the live event and slides via the registration link provided by the company or the Events and Presentations section of its investor website.

Will Protara (TARA) discuss regulatory feedback on TARA-002 during the December 3, 2025 call?

Yes, the company will provide an update on feedback from the U.S. Food and Drug Administration about a registrational path for TARA-002 in BCG-naïve patients.

Will a replay of the Protara (TARA) webcast be available after the December 3, 2025 presentation?

Yes, a replay of the webcast and accompanying slides will be archived for a limited time following the event.